Equity Profile

DYN

Dyne Therapeutics, Inc.

Health CareBiotechnology$3.9B

May11Mon

Post-Earnings Recap

ReportedQ1-2026Pre-Market7:30 AM EDT

Dyne Therapeutics Misses on Revenue, Stock Up 0.00%

Metric	Actual	Expected	Surprise
EPS	$-0.73	$-0.78	+1.35%
Revenue	$0M	$0M	—

management commentary, guidance changes, and full analysis available with Pro.

Dyne Therapeutics Misses on Revenue, Stock Up 0.00%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$-0.73	$-0.78	+1.35%
Revenue	$0M	$0M	—

Management Commentary

Tone: Unknown

No transcript is on record for this earnings call, so the analysis is based solely on numerical results.

What It Means

Dyne Therapeutics reported a narrower loss per share than analysts expected, which is a positive sign. However, the lack of revenue and guidance leaves uncertainty about future performance. The stock reaction remained unchanged, indicating that investors may be waiting for more information before making decisions.

Company Snapshot

Dyne Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for serious diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health.

$-0.78

Revenue

While no revenue is expected this quarter, any updates on future revenue streams could be critical for investor confidence.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Dyne Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for serious diseases. Operating in the health care sector, Dyne is particularly relevant as it seeks to address unmet medical needs through its advanced drug development programs.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

-5.31%

Avg Stock Reaction

+2.20%

Last Quarter Recap

In the last quarter, Dyne reported an EPS of $-0.76, slightly missing expectations but showing a small positive surprise. The stock reacted positively, gaining 3.39% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are anticipating a loss of $-0.78 per share this quarter, with no revenue expected. The market is closely watching for any signs of progress in Dyne's drug development pipeline.

Bull Case

If Dyne can exceed EPS expectations and provide positive updates on its drug candidates, it could boost investor sentiment and lead to a significant stock price increase.

Bear Case

Conversely, if Dyne fails to meet EPS expectations or provides no new insights into its pipeline, it could lead to a sharp decline in stock price.

Key Metrics to Watch

EPS

$-0.78

Earnings per share is a key indicator of the company's profitability and financial health.

Revenue

$0M

While no revenue is expected this quarter, any updates on future revenue streams could be critical for investor confidence.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Dyne's EPS exceed the consensus estimate of $-0.78?

A better-than-expected EPS could signal improved operational efficiency and boost investor confidence.

What updates will Dyne provide regarding its drug development pipeline?

Investors will be keen to hear about any advancements or setbacks in the pipeline, as this could significantly impact future revenue potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Dyne's potential for a surprise positive EPS, as recent operational improvements may not be fully reflected in consensus estimates.

Supporting Evidence

The company has a history of surprising the market, with a 50% EPS beat rate in the last eight quarters.

The options market is pricing in a large move, indicating that investors expect significant news.

Insider selling could suggest that insiders are taking profits, but it may not reflect the company's long-term potential.

Key Risk

If Dyne can show any signs of progress in its drug pipeline, it could significantly alter the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Dyne can turn around its financial performance and provide clarity on its future growth prospects.

Bull Confirmed If

An EPS of $-0.64 or better would confirm the bull case, indicating improved financial performance.

Bear Confirmed If

An EPS worse than $-1.08 would confirm the bear case, suggesting ongoing challenges in the business.

Pre-Earnings Positioning

Options Market

Implied Move

±29.97%

Historical Avg

±6.0%

Pricing rich

The options market is pricing in a significant potential move in either direction, indicating heightened uncertainty ahead of the earnings report.

Options are pricing ±30.0% while DYN has averaged ±6.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

52.5%

Calls (9K)P/C Ratio: 10.00Puts (3K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Dyne beats EPS expectations, history suggests a potential stock increase of around 5.4%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the market may react cautiously, leading to a muted response.

Miss

If Dyne misses EPS expectations, history suggests a potential decline of around 7.1%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the status of drug candidates in development.
2Management's commentary on operational efficiencies and cost management.
3Insights into potential partnerships or collaborations.
4Guidance on future revenue streams or timelines for product launches.
5Responses to analyst questions regarding insider selling and its implications.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May8

AMRReported

Alpha Metallurgical Resources, Inc.

RecapView

May8

PPLReported

Company Snapshot

Dyne Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for serious diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health.

$-0.78

Revenue

While no revenue is expected this quarter, any updates on future revenue streams could be critical for investor confidence.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

-5.31%

Avg Stock Reaction

+2.20%

Last Quarter Recap

In the last quarter, Dyne reported an EPS of $-0.76, slightly missing expectations but showing a small positive surprise. The stock reacted positively, gaining 3.39% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are anticipating a loss of $-0.78 per share this quarter, with no revenue expected. The market is closely watching for any signs of progress in Dyne's drug development pipeline.

Bull Case

If Dyne can exceed EPS expectations and provide positive updates on its drug candidates, it could boost investor sentiment and lead to a significant stock price increase.

Bear Case

Conversely, if Dyne fails to meet EPS expectations or provides no new insights into its pipeline, it could lead to a sharp decline in stock price.

Key Metrics to Watch

EPS

$-0.78

Earnings per share is a key indicator of the company's profitability and financial health.

Revenue

$0M

While no revenue is expected this quarter, any updates on future revenue streams could be critical for investor confidence.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Dyne's EPS exceed the consensus estimate of $-0.78?

A better-than-expected EPS could signal improved operational efficiency and boost investor confidence.

What updates will Dyne provide regarding its drug development pipeline?

Investors will be keen to hear about any advancements or setbacks in the pipeline, as this could significantly impact future revenue potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Dyne's potential for a surprise positive EPS, as recent operational improvements may not be fully reflected in consensus estimates.

Supporting Evidence

The company has a history of surprising the market, with a 50% EPS beat rate in the last eight quarters.

The options market is pricing in a large move, indicating that investors expect significant news.

Insider selling could suggest that insiders are taking profits, but it may not reflect the company's long-term potential.

Key Risk

If Dyne can show any signs of progress in its drug pipeline, it could significantly alter the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Dyne can turn around its financial performance and provide clarity on its future growth prospects.

Bull Confirmed If

An EPS of $-0.64 or better would confirm the bull case, indicating improved financial performance.

Bear Confirmed If

An EPS worse than $-1.08 would confirm the bear case, suggesting ongoing challenges in the business.

Pre-Earnings Positioning

Options Market

Implied Move

±29.97%

Historical Avg

±6.0%

Pricing rich

The options market is pricing in a significant potential move in either direction, indicating heightened uncertainty ahead of the earnings report.

Options are pricing ±30.0% while DYN has averaged ±6.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

52.5%

Calls (9K)P/C Ratio: 10.00Puts (3K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Dyne beats EPS expectations, history suggests a potential stock increase of around 5.4%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the market may react cautiously, leading to a muted response.

Miss

If Dyne misses EPS expectations, history suggests a potential decline of around 7.1%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the status of drug candidates in development.
2Management's commentary on operational efficiencies and cost management.
3Insights into potential partnerships or collaborations.
4Guidance on future revenue streams or timelines for product launches.
5Responses to analyst questions regarding insider selling and its implications.